"8"^^ . "Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients"@en . "8"^^ . "15110" . . "L\u00E9\u010Dba chronick\u00E9 myeloidn\u00ED leuk\u00E9mie (CML) rezistentn\u00ED na imatinib (IM) je obohacena o druhou generaci tyrozinkin\u00E1zov\u00FDch inhibitor\u016F (TKI), o dasatinib (DAS) a nilotinib. Rozhodnut\u00ED o zm\u011Bn\u011B terapie lze podpo\u0159it testem citlivosti leukemick\u00FDch bun\u011Bk na jednotliv\u00E9 TKI in vitro, kter\u00FD umo\u017E\u0148uje sledovat m\u00EDru \u00FA\u010Dinnosti TKI na z\u00E1klad\u011B detekce inhibice fosforylace sign\u00E1ln\u00EDch molekul, kter\u00E9 jsou substr\u00E1tem Bcr-Abl tyrozinkin\u00E1zy."@cs . . "RIV/61989592:15110/08:00007429" . . "RIV/61989592:15110/08:00007429!RIV09-MSM-15110___" . . "Faber, Edgar" . . . "Veselovsk\u00E1, Jitka" . . "V\u00FDznam testu sensitivity leukemick\u00FD bun\u011Bk na inhibitory kin\u00E1z in vitro p\u0159i rozhodov\u00E1n\u00ED o l\u00E9\u010Db\u011B imatinibem a dasatinibem u nemocn\u00FDch s CML"@cs . . "Haematologica: the hematology journal" . . . . "Mojz\u00EDkov\u00E1, Ren\u00E1ta" . "93" . "Z(MSM6198959205)" . "Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients"@en . "IT - Italsk\u00E1 republika" . . "Divok\u00FD, Vladim\u00EDr" . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . . . . . "Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optimem I (Gibco) a"@en . "Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients" . "Jaro\u0161ov\u00E1, Marie" . . "Holzerov\u00E1, Milena" . "Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients" . . "1"^^ . "V\u00FDznam testu sensitivity leukemick\u00FD bun\u011Bk na inhibitory kin\u00E1z in vitro p\u0159i rozhodov\u00E1n\u00ED o l\u00E9\u010Db\u011B imatinibem a dasatinibem u nemocn\u00FDch s CML"@cs . . "[8D7275325B11]" . . "S1" . . "chronic myeloid leukemia; tyrosine kinase inhibitor; imatinib resistance; src kinase"@en . . . "0390-6078" . "Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optimem I (Gibco) a" . "Indr\u00E1k, Karel" . "401811" .